Get the Daily Brief
Latest Biotech News
AI and compute scale speed drug discovery and virtual cell modeling
New physics‑grounded AI models and collaborations are accelerating early drug discovery and biological simulation. Researchers showcased Boltz‑2 and related large quantitative models that predict...
Nanoparticles reinvigorate ovarian cancer immunotherapy
Two independent preclinical programs reported that nanoparticle platforms can concentrate IL‑12 in ovarian tumors and boost responses to checkpoint blockade. MIT and collaborators described...
Bird‑flu spillovers push phage therapy and antiviral innovation
Rising HPAI (H5N1) spillovers into livestock and sporadic human cases have refocused research on complementary countermeasures, including bacteriophage therapeutics to treat secondary bacterial...
Pfizer sues to block Novo’s Metsera bid—Delaware court showdown
Pfizer filed suit in Delaware’s Court of Chancery against Metsera and Novo Nordisk to stop Novo’s unsolicited takeover approach and enforce a September buyout agreement, the companies announced...
FDA halts Intellia’s CRISPR Phase 3 trials after liver safety signals
The U.S. Food and Drug Administration placed a clinical hold on Intellia’s two Phase 3 studies of its in vivo CRISPR editing therapy nexiguran ziclumeran (nex‑z) for transthyretin amyloidosis...
UCL–UCLA gene therapy for ADA‑SCID hits curative milestone in long follow‑up
A joint UCL–UCLA clinical program reported multi‑year data showing their lentiviral gene therapy for ADA‑SCID produced immune reconstitution in treated children with a roughly 95% success rate and...
Baby KJ model: FDA guidance and one‑off CRISPR therapies move toward scalability
Researchers who created the bespoke CRISPR treatment for Baby KJ published their FDA interactions and described plans to translate the single‑patient emergency program into a replicable regulatory...
IL‑12 nanoparticles reverse ovarian tumor immune suppression in mice
MIT researchers engineered polymer‑coated nanoparticles that deliver IL‑12 directly into ovarian tumors and dramatically improved responses to immune checkpoint inhibitors in preclinical models....
Scalable human kidney organoids integrated into porcine kidneys—first transplant success
Researchers at the Institute for Bioengineering of Catalonia (IBEC) reported a scalable method to produce thousands of human kidney organoids and successfully integrate them into perfused porcine...
AI models accelerate drug discovery: Boltz‑2 and foundation models enter the lab
Academic and industry teams reported major advances in AI for small‑molecule discovery and biochemical simulation. MIT and Recursion released Boltz‑2, an open‑source model that predicts ligand...
Boosting Cas9 nuclear entry: internal NLS insertions raise editing efficiency
A University of California, Berkeley team reported a protein engineering strategy that improves CRISPR‑Cas9 nuclear import by inserting multiple nuclear localization signals (NLS) into internal...
4DMT sells APAC rights to fund phase 3—Otsuka deal backs retinal gene therapy
4D Molecular Therapeutics agreed to sell Asia‑Pacific rights to its retinal gene therapy 4D‑150 to Otsuka Pharmaceutical for $85 million upfront and up to $336 million in milestones, the companies...
Patent cliff looms: $230B of blockbusters face 2026–2029 expiries
GEN released an analysis identifying the top 20 drugs whose key U.S. patents expire between 2026 and 2029, representing roughly $176–230 billion in combined annual sales at risk. The list and...
Pfizer sues to enforce Metsera deal — Novo Nordisk counters with higher bid
Pfizer filed suit in the Delaware Court of Chancery to block Metsera’s board from terminating a $4.9 billion merger agreement after Novo Nordisk surfaced with a higher, unconventional takeover...
FDA places Intellia’s CRISPR candidate on hold after liver events
The U.S. Food and Drug Administration has imposed a clinical hold on Intellia Therapeutics’ two Phase 3 studies of nexiguran ziclumeran (nex‑z), a CRISPR‑based in vivo genome‑editing therapy for...
UCL–UCLA gene therapy posts near‑complete success in ADA‑SCID follow‑up
A joint University College London and UCLA gene‑therapy program reported multi‑year follow‑up data showing a ~95% success rate and no serious safety signals in children treated for ADA‑SCID,...
Baby KJ case spurs pathway playbook for bespoke CRISPR therapies
Researchers behind the Philadelphia case known as 'Baby KJ' have published their FDA interactions and are publicly mapping a regulatory pathway to scale bespoke, patient‑specific CRISPR therapies....
Scalable human kidney organoids integrated into porcine kidneys ex vivo
Researchers at the Institute for Bioengineering of Catalonia and collaborators reported a scalable method to produce thousands of human kidney organoids and successfully integrate them into...
Cloud‑connected tubeless pump and CGM turbulence reshape diabetes device landscape
Real‑world data from over 14,000 users in France show that a tubeless insulin pump integrated with a cloud platform improved diabetes management metrics, according to a multicenter dataset. The...
mRNA’s promise tested: Moderna’s struggles and a surprise oncology signal
Moderna, once the poster child of mRNA therapeutics, is under pressure from falling COVID vaccine revenues, government contract cancellations and investor demands to reduce spending, according to...